Safety and Efficacy of Amlotinib in the Treatment of Recurrent Craniopharyngioma
Aims: 1. To assess progression-free survival (PFS) and overall survival (OS) of patients with recurrent craniopharyngiomas treated with amrlotinib. 2. To analyze the disease control rate (DCR) of the Anrotinib treatment regimen in patients with recurrent craniopharyngiomas, including the proportion of patients in complete remission, partial remission and stable disease. 3. Monitor and evaluate the safety of amrutinib, especially the occurrence of drug-related adverse events (AEs) .
• Age 18-75 years old, regardless of gender
• recurrent craniopharyngioma (recurrence after total resection or regrowth of residual tumor) confirmed by pathology and imaging data
• predominantly cystic or solid recurrence of the tumor
• measurable lesions (according to the RECIST criteria)
• Karnofsky score ≥ 70, expected survival ≥ 3 months
• laboratory parameters (liver and kidney function, blood tests, etc.) within the normal range or under control
• signed informed consent and willing to participate in the study